How Should Clinical Operators Determine The Initial Dosage For Plaque Psoriasis When Using Medical Laser Phototherapy Equipment? Optimize Treatment With Individualized Dosing Based On Med And Skin Type.

Initial dosage should be determined from the equipment’s validated protocol, the patient’s Minimal Erythema Dose (MED), Fitzpatrick skin type, and plaque characteristics. When MED testing is available, the starting fluence is generally calculated as a device-specific multiple of the patient’s MED, adjusted for plaque thickness, location, and tanning. When a protocol permits treatment without prior MED testing, operators can select a starting fluence using skin type and plaque induration, then adjust it according to the tissue response observed after treatment.

The safest initial dose is the lowest protocol-supported fluence expected to produce a therapeutic response without excessive erythema, pain, blistering, or thermal injury. MED-based dosing is more individualized; direct fluence selection is faster but requires conservative starting values and careful follow-up.

Establish the Starting Dose

Use MED Testing When Practical

MED testing measures the amount of energy required to produce a defined minimal erythematous response on normal skin. The baseline MED can then be used to calculate an individualized starting fluence for targeted treatment.

The appropriate multiplier must come from the specific device’s clinical protocol. As a general framework from the referenced protocols, thin, non-tanned plaques may begin at approximately 1 to 2 times MED, while thick or tanned plaques on resistant sites such as the elbows or knees may require a higher multiplier, potentially up to 4 times MED.

Adjust for Plaque Characteristics

Plaque induration, thickness, hyperkeratosis, location, and tanning affect the initial dose selection. Thicker and more resistant plaques generally require more energy than thin plaques, but a higher dose also increases the risk of pain, excessive erythema, blistering, and post-inflammatory hyperpigmentation.

The operator should assess each treatment area rather than applying one dose uniformly to every plaque. Normal skin and thin plaques should not automatically receive the same fluence used for thick, resistant lesions.

Use Direct Fluence Selection When MED Testing Is Not Used

Some validated protocols allow the operator to select an initial fluence directly from the patient’s Fitzpatrick skin type and plaque induration. The referenced starting ranges are:

Plaque induration	Fitzpatrick types I–III	Fitzpatrick types IV–VI
Mild	300 mJ/cm²	400 mJ/cm²
Moderate	500–600 mJ/cm²	500–600 mJ/cm²
Severe	700 mJ/cm²	900 mJ/cm²

These values should be treated as protocol examples, not universal prescriptions. The equipment’s labeling, treatment manual, training requirements, and clinical indications take precedence.

Match Fluence to the Treatment Objective

Start Conservatively on Sensitive or Pigmented Skin

Patients with darker Fitzpatrick skin types may be more susceptible to pigmentary changes after inflammation. A higher starting fluence may be specified for some protocols, but the operator should still account for tanning, prior treatment response, lesion location, and the patient’s tolerance.

Sensitive sites and areas with thinner plaques may warrant a lower starting value than thick plaques elsewhere on the body. The objective is controlled therapeutic inflammation, not immediate maximal erythema.

Respect the Device’s Delivery Range

For 308 nm targeted phototherapy, referenced clinical ranges may extend from approximately 100 to 2,100 mJ/cm², with adjustments made in defined increments such as 50 mJ/cm². The allowable range and increment depend on the device.

Operators should adjust either exposure time or pulse delivery only as permitted by the equipment manufacturer and clinical protocol. Fluence calculations must account for the device’s actual output and treatment geometry.

Do Not Assume That Higher Is Better

High multiples of MED may clear plaques more rapidly but can also produce painful erythema or blistering. Moderate MED-based dosing, such as approximately 3 to 4 times MED in suitable protocols, is generally presented as a more tolerable clinical approach than deliberately using very high doses.

The initial prescription should therefore balance plaque resistance against patient safety and the expected follow-up interval.

Use the Response to Guide Subsequent Doses

Evaluate the Treated Area After Treatment

Tissue response should be assessed during the appropriate post-treatment window, commonly beginning around 24 hours and extending through the protocol’s specified observation period. Relevant findings include erythema, pain, tenderness, blistering, plaque thinning, reduced scale, and overall improvement.

The operator should document the fluence, treatment area, overlap status, symptoms, and delayed skin response. This record supports consistent dose escalation or reduction at later sessions.

Apply Protocol-Based Dose Changes

The referenced adjustment framework is:

No erythema or plaque improvement: increase fluence by approximately 15% to 25%.
Minimal response: increase fluence by approximately 15%.
Good improvement with acceptable tolerance: maintain the dose.
Significant improvement: consider reducing fluence by approximately 25% to limit unnecessary inflammation and pigmentary risk.
Moderate to severe erythema or pain: reduce fluence by approximately 25%, or follow the device-specific adverse-response protocol.
Blistering or marked tenderness: stop treatment to the affected area until fully healed and reassess the treatment plan.

These percentages are protocol-dependent. The treating clinician should not escalate automatically when the patient has delayed or worsening inflammation.

Avoid Overlapping Exposure

The same area should not be treated twice during one session. Excessive overlap can concentrate energy and cause severe thermal injury, particularly when treating sharply defined plaques or using a small treatment spot.

Blistered or injured skin must not be treated directly until it has fully healed. Any treatment-area mapping, shielding, and spot-placement requirements in the device instructions should be followed precisely.

Understanding the Trade-offs

MED Testing Improves Individualization

MED testing accounts for patient-specific sensitivity and can help reduce the risk of starting too high or too low. Its disadvantages are the additional time, workflow complexity, and need for correct test-site interpretation.

MED testing also does not eliminate the need to adjust for plaque thickness, tanning, location, prior phototherapy, and clinical response.

Direct Selection Improves Workflow

Direct selection by Fitzpatrick skin type and plaque induration can simplify the first visit and support a faster clinical workflow. Its limitation is that skin type and visual plaque assessment are imperfect substitutes for an individualized MED.

When direct dosing is used, conservative selection and disciplined follow-up become especially important.

Concentrated Treatment Increases the Consequences of Error

Targeted laser phototherapy concentrates energy on lesions rather than distributing it across a broad treatment field. This can make treatment efficient, but inaccurate dosing, repeated exposure, or overlapping spots can produce disproportionate local injury.

The operator should prioritize dose accuracy, complete documentation, patient instructions, and timely assessment of delayed reactions.

Device Protocols Are Not Interchangeable

Fluence values from one laser or lamp should not be transferred automatically to another device. Wavelength, output calibration, spot size, pulse characteristics, delivery mode, and regulatory labeling can all affect how a nominal fluence behaves clinically.

The manufacturer’s instructions and the supervising clinician’s protocol should govern the final starting dose.

How to Apply This to Clinical Practice

Use the following decision framework within the device’s validated indication and under appropriate clinical supervision:

If your primary focus is individualized dosing: Perform MED testing when practical, then apply the device-specific MED multiplier while adjusting for plaque thickness, location, tanning, and patient tolerance.
If your primary focus is workflow efficiency: Use the approved direct-selection table based on Fitzpatrick skin type and plaque induration, starting at approximately 300–400 mJ/cm² for mild plaques, 500–600 mJ/cm² for moderate plaques, or 700–900 mJ/cm² for severe plaques.
If your primary focus is treatment safety: Begin with a protocol-supported conservative fluence, avoid overlap, inspect the delayed tissue response, and reduce or stop treatment when significant erythema, pain, tenderness, or blistering occurs.
If your primary focus is progressive clearance: Reassess the plaque and surrounding skin after each session, increase only when the response is inadequate, and maintain or reduce the dose when improvement is already occurring.

A sound initial-dose decision combines validated device guidance, patient-specific sensitivity, plaque assessment, and measured response rather than relying on a single fluence value.

Summary Table:

Method	Best For	Starting Dose	Advantages	Disadvantages
MED Testing	Individualized dosing	1–4× MED depending on plaque thickness & tanning	Personalized; reduces risk of over/underdosing	Time-consuming; requires interpretation
Direct Selection	Workflow efficiency	300–900 mJ/cm² based on skin type & induration	Fast; simple	Less personalized; requires conservative start & follow-up

Ensure precise and safe laser psoriasis treatments with BELIS's advanced phototherapy devices. Our medical-grade equipment and clinical protocols support individualized dosing, helping clinics and premium salons achieve optimal outcomes. Contact our experts today to learn how BELIS can elevate your practice.